Skip to main content

Table 4 Association of Polymorphisms cMyc-N11S and p27-V109G with Breast Cancer Survival

From: Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis

  Distant Recurrence Free Survival Overall Survival
  NR/N unadjusted HR (95% CI) adjusted1 HR (95% CI) ND/N unadjusted HR (95% CI) adjusted1 HR (95% CI)
cMyc-N11S (A>G)       
AA 108/861 1.00 1.00 77/876 1.00 1.00
AG/GG 5/74 0.54 (0.22–1.32) 0.50 (0.20–1.23) 5/76 0.77 (0.31–1.91) 0.63 (0.23–1.75)
p-value   0.17 0.13   0.58 0.38
p27-V109G (T>G)       
TT 67/570 1.00 1.00 47/579 1.00 1.00
TG/GG 46/367 1.05 (0.72–1.53) 1.00 (0.68–1.48) 35/375 1.11 (0.72–1.72) 0.97 (0.61–1.55)
p-value   0.79 0.99   0.65 0.90
Combined       
cMyc AA + p27 TT 63/522 1.00 1.00 43/529 1.00 1.00
cMyc AA + p27 TG/GG 45/330 3.34 (0.46–24.1) 3.83 (0.53–27.7) 34/338 2.23 (0.31–16.2) 2.57 (0.35–18.8)
cMyc AG/GG + p27 TT 4/45 3.70 (0.51–26.8) 3.71 (0.51–27.0) 4/47 2.64 (0.36–19.3) 2.45 (0.33–18.0)
cMyc AG/GG + p27 TG/GG 1/28 2.40 (0.27–21.5) 2.37 (0.27–21.3) 1/28 2.37 (0.26–21.2) 2.35 (0.26–21.1)
p-value   0.51 0.47   0.73 0.83
  1. N number at risk; NR number of distant recurrences; ND number of deaths; 1 adjusted for age, nodal involvement, grade, ethnicity, treatment and T stage